Regeneron and CytomX extend cancer therapy partnership to $4bn deal

Regeneron Pharmaceuticals and CytomX have expanded their research and licensing partnership to develop conditionally activated bispecific antibody cancer therapies. The partnership brings together CytomX’s biologic masking technology and Regeneron’s expertise in bispecific antibodies. CytomX will receive a $37m payment for two targets, with Regeneron able to select six additional targets. Credit: viewimage / Shutterstock.com. Regeneron Pharmaceuticals and CytomX have expanded their research and licensing partnership to develop conditionally activated bispecific antibody cancer therapies, with the deal’s total potential value rising to up to $4bn. The collaboration combines CytomX’s Probody technology with Regeneron’s Veloci‑Bi bispecific platform to target hard‑to‑treat tumour types.…

Source: Pharmaceutical Technology